Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. More Details
Flawless balance sheet with exceptional growth potential.
Share Price & News
How has Novavax's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NVAX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: NVAX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: NVAX underperformed the US Biotechs industry which returned 21.4% over the past year.
Return vs Market: NVAX underperformed the US Market which returned 34.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Novavax's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall StNovavax, Inc. (NASDAQ:NVAX): When Will It Breakeven?
4 weeks ago | Simply Wall StNovavax's (NASDAQ:NVAX) Wonderful 674% Share Price Increase Shows How Capitalism Can Build Wealth
1 month ago | Simply Wall StHow Much Of Novavax, Inc. (NASDAQ:NVAX) Do Institutions Own?
Is Novavax undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NVAX ($188.57) is trading below our estimate of fair value ($2044.49)
Significantly Below Fair Value: NVAX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NVAX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: NVAX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NVAX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NVAX is overvalued based on its PB Ratio (13.4x) compared to the US Biotechs industry average (2.8x).
How is Novavax forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NVAX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: NVAX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: NVAX's is expected to become profitable in the next 3 years.
Revenue vs Market: NVAX's revenue (24.1% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: NVAX's revenue (24.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NVAX's Return on Equity is forecast to be very high in 3 years time (153.9%).
How has Novavax performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NVAX is currently unprofitable.
Growing Profit Margin: NVAX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NVAX is unprofitable, and losses have increased over the past 5 years at a rate of 5.7% per year.
Accelerating Growth: Unable to compare NVAX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NVAX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (32.6%).
Return on Equity
High ROE: NVAX has a negative Return on Equity (-59.2%), as it is currently unprofitable.
How is Novavax's financial position?
Financial Position Analysis
Short Term Liabilities: NVAX's short term assets ($2.2B) exceed its short term liabilities ($1.2B).
Long Term Liabilities: NVAX's short term assets ($2.2B) exceed its long term liabilities ($360.7M).
Debt to Equity History and Analysis
Debt Level: NVAX's debt to equity ratio (31%) is considered satisfactory.
Reducing Debt: NVAX's debt to equity ratio has reduced from 167.1% to 31% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable NVAX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: NVAX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 24.2% per year.
What is Novavax current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NVAX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NVAX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NVAX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NVAX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NVAX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Stan Erck (73 yo)
Mr. Stanley Charles Erck, also known as Stan, has been the Chief Executive Officer and President of Novavax, Inc. since April 19, 2011 and has been its Director since June 2009. Mr. Erck served as the Exec...
CEO Compensation Analysis
Compensation vs Market: Stan's total compensation ($USD48.09M) is above average for companies of similar size in the US market ($USD11.16M).
Compensation vs Earnings: Stan's compensation has increased whilst the company is unprofitable.
Experienced Management: NVAX's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Experienced Board: NVAX's board of directors are seasoned and experienced ( 10.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: NVAX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 162.3%.
Novavax, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Novavax, Inc.
- Ticker: NVAX
- Exchange: NasdaqGS
- Founded: 1987
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$13.969b
- Shares outstanding: 74.08m
- Website: https://www.novavax.com
Number of Employees
- Novavax, Inc.
- 21 Firstfield Road
- United States
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candi...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/08/03 23:34|
|End of Day Share Price||2021/08/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.